Robert B. Laprairie

University of Saskatchewan

2 papers in the library · 5 citations · publishing 2023-2024

Papers

Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method

Journal of Chromatography A July 4, 2024 Amir Khajavinia, Déborah Michel, Udoka C. Ezeaka et al. 4 citations

Psilocin, the active metabolite of the psychedelic compound psilocybin, is being studied for treating anxiety, depression, and PTSD. Evaluating its pharmacokinetics is essential for drug development. During reversed-phase liquid chromatography analysis of mouse plasma, a previously unreported interference was encountered. The interference was identified as tryptophan using exact mass measurement and MS/MS analysis. A fast and reliable hydrophilic interaction liquid chromatography–tandem mass spectrometry (HILIC-MS/MS) method was developed and validated that separates psilocin from tryptophan, achieving a lower limit of quantification of 0.5 ng/ml. The method was successfully applied to a pharmacokinetic study in C57BL/6 mice, determining psilocin concentrations in all analyzed plasma samples.

DOI: 10.1016/j.chroma.2024.465123 Chemistry Electrospray ionization Selected reaction monitoring Hydrophilic interaction chromatography +4

Addressing the Current Knowledge and Gaps in Research SurroundingLysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in RodentModels

Current Topics in Medicinal Chemistry July 6, 2023 Udoka C. Ezeaka, Hye Ji J. Kim, Robert B. Laprairie 1 citation

LSD, psilocybin, and psilocin are being evaluated as potential treatments for depression, anxiety, substance use disorder, and other psychiatric conditions. Pre-clinical research in rodents is key to their drug development. This review summarizes evidence on these compounds in rodent models of the psychedelic experience, behavior, substance use, alcohol consumption, drug discrimination, anxiety, depression-like behavior, stress response, and pharmacokinetics. The authors identify three knowledge gaps for future research: sex differences, oral dosing instead of injection, and chronic dosing regimens. A thorough understanding of the in vivo pharmacology of these compounds may aid their clinical use and serve as controls for developing novel psychedelic therapeutics.

DOI: 10.2174/1568026623666230705151922 Psilocybin Lysergic acid diethylamide Anxiety Hallucinogen +6